Loading...
•
Jun 30, 2024
Generation Bio Q2 2024 Earnings Report
Reported second quarter 2024 financial results.
Key Takeaways
Generation Bio reported a net loss of $20.4 million, or $0.31 per share, for the second quarter of 2024. The company's cash, cash equivalents, and marketable securities were $216.9 million as of June 30, 2024, expected to fund operations into the second half of 2027.
Cash, cash equivalents, and marketable securities were $216.9 million as of June 30, 2024.
Cash balance is expected to fund operations into 2H 2027.
Research and development expenses were $16.4 million for the quarter ended June 30, 2024.
Net loss was $20.4 million, or $0.31 basic and diluted net loss per share, for the quarter ended June 30, 2024.
Generation Bio
Generation Bio
Generation Bio Revenue by Segment
Revenue by Segment
Collaboration Revenue
CapyFin.com Forward Guidance
The company continues to believe that its cash, cash equivalents, and marketable securities will fund its operating expenses and capital expenditures into the second half of 2027.